Amplyx Pharmaceuticals, a San Diego, CA-based company developing novel antifungal agents for life-threatening fungal infections, raised $67m in Series C financing.
The round was led by Sofinnova Venture Partners with participation from other new investors Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital and existing investors New Enterprise Associates, RiverVest Venture Partners, 3×5 RiverVest II and BioMed Ventures. In conjunction with the financing, Anand Mehra, M.D., managing partner at Sofinnova Ventures, and Johan Kördel, Ph.D., senior partner at Lundbeckfonden Ventures, will join Amplyx’ board of directors.
Led by Ciara Kennedy, Ph.D., chief executive officer, Amplyx Pharmaceuticals is developing novel, broad-spectrum antifungal agents for the treatment of life-threatening fungal infections.
The company, which has raised $118.5m in venture capital and secured more than $10m in grants from the National Institutes of Health, will use the proceeds to advance the clinical development of APX001, its broad-spectrum antifungal agent, to treat life threatening fungal infections. Intravenous and oral formulations of APX001 have been evaluated in a Phase 1 clinical program, with Phase 2 clinical trials in invasive aspergillosis and invasive candidiasis planned for initiation later this year.